Thema: News: Intra-arterial delivery of endostatin gene to brain tumors
News: Intra-arterial delivery of endostatin gene to brain tumors
Tina[a]
30.05.2004 21:45:34
Gene Ther. 2004 May 27
Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure.
Barnett FH, Scharer-Schuksz M, Wood M, Yu X, Wagner TE, Friedlander M.
1Department of Cell Biology, The Scripps Research Institute, La Jolla, CA, USA.
Glioblastoma multiforme (GBM) is an incurable malignant brain tumor, usually fatal within 1 year of diagnosis. Using a syngeneic rat 9L gliosarcoma model, we have developed a novel drug delivery method in which naked plasmid DNA is selectively targeted to brain tumors via intra-arterial injection. Using a plasmid encoding the antiangiogenic endostatin, transgene expression can be detected in tumor cells in vivo, and therapeutic efficacy is observed. Administration of this plasmid resulted in an 80% tumor volume reduction 1 week after treatment and enhanced survival time by up to 47%. Treated tumors exhibited a 40% decrease in the number of tumor vessels; ultrastructural analysis of remaining tumor vessels demonstrated a number of changes including markedly narrowed or collapsed lumens. We conclude that intra-arterial injection of plasmids selectively targets therapeutic genes to CNS neoplasms. This method of gene therapy holds promise for the treatment of these highly malignant brain tumors.Gene Therapy advance online publication, 27 May 2004; doi:10.1038/sj.gt.3302287
Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure.
Barnett FH, Scharer-Schuksz M, Wood M, Yu X, Wagner TE, Friedlander M.
1Department of Cell Biology, The Scripps Research Institute, La Jolla, CA, USA.
Glioblastoma multiforme (GBM) is an incurable malignant brain tumor, usually fatal within 1 year of diagnosis. Using a syngeneic rat 9L gliosarcoma model, we have developed a novel drug delivery method in which naked plasmid DNA is selectively targeted to brain tumors via intra-arterial injection. Using a plasmid encoding the antiangiogenic endostatin, transgene expression can be detected in tumor cells in vivo, and therapeutic efficacy is observed. Administration of this plasmid resulted in an 80% tumor volume reduction 1 week after treatment and enhanced survival time by up to 47%. Treated tumors exhibited a 40% decrease in the number of tumor vessels; ultrastructural analysis of remaining tumor vessels demonstrated a number of changes including markedly narrowed or collapsed lumens. We conclude that intra-arterial injection of plasmids selectively targets therapeutic genes to CNS neoplasms. This method of gene therapy holds promise for the treatment of these highly malignant brain tumors.Gene Therapy advance online publication, 27 May 2004; doi:10.1038/sj.gt.3302287
Tina[a]
